Bio-Techne Navigates Mixed Market Signals with Steady Q4, Eyes Growth in Key Verticals
Bio-Techne (NASDAQ:TECH) delivered Q4 2025 results that edged past analyst forecasts, with flat year-over-year revenue of $295.9 million overshadowed by stronger-than-expected profitability and margin expansion, as the company manages a bifurcated demand environment.